Yahoo
NasdaqCM - Nasdaq Real Time Price USD

DBV Technologies S.A. (DBVT)

10.65 +0.53 (+5.19%)
At close: October 28 at 4:00:00 PM EDT
9.51 -1.14 (-10.70%)
Pre-Market: 7:11:46 AM EDT
Trade DBVT on Coinbase
DBVT Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for DBVT
  • Previous Close 10.12
  • Open 10.09
  • Bid 10.52 x 100
  • Ask 9.72 x 300
  • Day's Range 10.03 - 10.86
  • 52 Week Range 8.63 - 26.18
  • Volume 225,697
  • Avg. Volume 363,806
  • Market Cap (intraday) 669.336M
  • Beta (5Y Monthly) -0.24
  • PE Ratio (TTM) --
  • EPS (TTM) -3.50
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 38.56
  • Zacks Rating Neutral

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

www.dbv-technologies.com

170

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

DBVT
44.56%
CAC 40 (^FCHI)
2.33%

1-Year Return

DBVT
31.51%
CAC 40 (^FCHI)
2.94%

3-Year Return

DBVT
397.66%
CAC 40 (^FCHI)
17.13%

5-Year Return

DBVT
74.02%
CAC 40 (^FCHI)
16.53%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.44M
Earnings -57.87M
Profit Margin -4,031.25%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-40M
-20M
0
-7000.0%
-6000.0%
-5000.0%

Analyst Insights

View More

Analyst Price Targets

5.67
38.56 Average
10.65 Current
55.05 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/30/2026
Analyst Citizens
Rating Action Maintains
Rating Market Outperform
Price Action Raises
Price Target 47 -> 55

Statistics

View More

Valuation Measures

Annual
As of 10/28/2026
  • Market Cap

    631.66M

  • Enterprise Value

    482.36M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.68

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -60.61%

  • Return on Equity (ttm)

    -142.68%

  • Revenue (ttm)

    5.04M

  • Net Income Avi to Common (ttm)

    -175.95M

  • Diluted EPS (ttm)

    -3.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    174.9M

  • Total Debt/Equity (mrq)

    4.80%

  • Levered Free Cash Flow (ttm)

    -104.85M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

10.65 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: